Metraipolis › archive › dc_191fffc67e25

Rationale and Design of the Cancer Immunotherapy Evidence Living (CIEL) Library: A Continuously Updated Clinical Trial Database of Cancer Immunotherapies — Europe PMC PMID:42005618

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42005618
DOI: 10.1002/hsr2.72221
License (as archived): solo-consultazione
Archived: 2026-10-17T04:09:07.031Z
SHA-256 of the archived text: c03051d57f9d6f474878356f103106d47c9498476055796383cea21a7680f60f
Stable URL of this page: https://metraipolis.com/documento/dc_191fffc67e25

How to cite

Rationale and Design of the Cancer Immunotherapy Evidence Living (CIEL) Library: A Continuously Updated Clinical Trial Database of Cancer Immunotherapies — Europe PMC PMID:42005618 — Europe PMC (en), https://europepmc.org/article/MED/42005618 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_191fffc67e25 (Metraipolis archive dc_191fffc67e25, sha256 c03051d57f9d6f474878356f103106d47c9498476055796383cea21a7680f60f)

BibTeX

@misc{dc191fffc67e25,
  title = {Rationale and Design of the Cancer Immunotherapy Evidence Living (CIEL) Library: A Continuously Updated Clinical Trial Database of Cancer Immunotherapies — Europe PMC PMID:42005618},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42005618},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_191fffc67e25; sha256 c03051d57f9d6f474878356f103106d47c9498476055796383cea21a7680f60f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42005618. Agents can read the archived copy with the MCP tool read_document.